{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T03:50:09Z","timestamp":1774583409678,"version":"3.50.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00393-025-01620-4","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T13:40:42Z","timestamp":1740058842000},"page":"113-120","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["\u201eParadoxe Frakturen\u201c: pathologische Frakturen unter antiosteoporotischer und antirheumatischer Therapie","\u201cParadoxical fractures\u201d: pathological fractures under anti-osteoporotic and antirheumatic treatment"],"prefix":"10.1007","volume":"84","author":[{"given":"Edgar","family":"Wiebe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Hoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Buttgereit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"1620_CR1","volume-title":"S3-Leitlinie Antiresorptiva-assoziierte Kiefernekrosen","author":"E Schiegnitz","year":"2017","unstructured":"Schiegnitz\u00a0E, Hoefert\u00a0S, Otto\u00a0S, Pautke\u00a0C, Ristow\u00a0O, Voss\u00a0P, Gr\u00f6tz\u00a0KA (2017) S3-Leitlinie Antiresorptiva-assoziierte Kiefernekrosen (AWMF Registernummer: 007\u2013091)"},{"issue":"1","key":"1620_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","volume":"30","author":"AA Khan","year":"2015","unstructured":"Khan\u00a0AA, Morrison\u00a0A, Hanley\u00a0DA, Felsenberg\u00a0D, McCauley\u00a0LK, O\u2019Ryan\u00a0F et\u00a0al (2015) Diagnosis and management of osteonecrosis of the jaw: a\u00a0systematic review and international consensus. J\u00a0Bone Miner Res 30(1):3\u201323","journal-title":"J Bone Miner Res"},{"issue":"3","key":"1620_CR3","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1210\/jc.2004-0952","volume":"90","author":"CV Odvina","year":"2005","unstructured":"Odvina\u00a0CV, Zerwekh\u00a0JE, Rao\u00a0DS, Maalouf\u00a0N, Gottschalk\u00a0FA, Pak\u00a0CY (2005) Severely suppressed bone turnover: a\u00a0potential complication of alendronate therapy. J\u00a0Clin Endocrinol Metab 90(3):1294\u20131301","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1620_CR4","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s11914-018-0464-6","volume":"16","author":"J Starr","year":"2018","unstructured":"Starr\u00a0J, Tay\u00a0YKD, Shane\u00a0E (2018) Current understanding of epidemiology, pathophysiology, and management of atypical femur fractures. Curr Osteoporos Rep 16(4):519\u2013529","journal-title":"Curr Osteoporos Rep"},{"issue":"11","key":"1620_CR5","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1002\/jbmr.253","volume":"25","author":"E Shane","year":"2010","unstructured":"Shane\u00a0E, Burr\u00a0D, Ebeling\u00a0PR, Abrahamsen\u00a0B, Adler\u00a0RA, Brown\u00a0TD et\u00a0al (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a\u00a0task force of the American Society for Bone and Mineral Research. J\u00a0Bone Miner Res 25(11):2267\u20132294","journal-title":"J Bone Miner Res"},{"issue":"1","key":"1620_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jbmr.1998","volume":"29","author":"E Shane","year":"2014","unstructured":"Shane\u00a0E, Burr\u00a0D, Abrahamsen\u00a0B, Adler\u00a0RA, Brown\u00a0TD, Cheung\u00a0AM et\u00a0al (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a\u00a0task force of the American Society for Bone and Mineral Research. J\u00a0Bone Miner Res 29(1):1\u201323","journal-title":"J Bone Miner Res"},{"issue":"10","key":"1620_CR7","doi-asserted-by":"publisher","first-page":"e10681","DOI":"10.1002\/jbm4.10681","volume":"6","author":"J Everts-Graber","year":"2022","unstructured":"Everts-Graber\u00a0J, Bonel\u00a0H, Lehmann\u00a0D, Gahl\u00a0B, Hauselmann\u00a0H, Studer\u00a0U et\u00a0al (2022) Incidence of atypical femoral fractures in patients on osteoporosis therapy\u2011a registry-based cohort study. JBMR Plus 6(10):e10681","journal-title":"JBMR Plus"},{"issue":"18","key":"1620_CR8","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1010650","volume":"364","author":"J Schilcher","year":"2011","unstructured":"Schilcher\u00a0J, Michaelsson\u00a0K, Aspenberg\u00a0P (2011) Bisphosphonate use and atypical fractures of the femoral shaft. N\u00a0Engl J Med 364(18):1728\u20131737","journal-title":"N Engl J Med"},{"issue":"19","key":"1620_CR9","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1056\/NEJMc0910389","volume":"362","author":"CM Girgis","year":"2010","unstructured":"Girgis\u00a0CM, Sher\u00a0D, Seibel\u00a0MJ (2010) Atypical femoral fractures and bisphosphonate use. N\u00a0Engl J Med 362(19):1848\u20131849","journal-title":"N Engl J Med"},{"issue":"8","key":"1620_CR10","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1056\/NEJMoa1916525","volume":"383","author":"DM Black","year":"2020","unstructured":"Black\u00a0DM, Geiger\u00a0EJ, Eastell\u00a0R, Vittinghoff\u00a0E, Li\u00a0BH, Ryan\u00a0DS et\u00a0al (2020) Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. N\u00a0Engl J Med 383(8):743\u2013753","journal-title":"N Engl J Med"},{"issue":"2","key":"1620_CR11","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00198-015-3354-0","volume":"27","author":"SK Ramchand","year":"2016","unstructured":"Ramchand\u00a0SK, Chiang\u00a0CY, Zebaze\u00a0RM, Seeman\u00a0E (2016) Recurrence of bilateral atypical femoral fractures associated with the sequential use of teriparatide and denosumab: a\u00a0case report. Osteoporos Int 27(2):821\u2013825","journal-title":"Osteoporos Int"},{"issue":"2","key":"1620_CR12","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s00198-015-3355-z","volume":"27","author":"J Selga","year":"2016","unstructured":"Selga\u00a0J, Nunez\u00a0JH, Minguell\u00a0J, Lalanza\u00a0M, Garrido\u00a0M (2016) Simultaneous bilateral atypical femoral fracture in a\u00a0patient receiving denosumab: case report and literature review. Osteoporos Int 27(2):827\u2013832","journal-title":"Osteoporos Int"},{"issue":"8","key":"1620_CR13","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1210\/jc.2016-1801","volume":"101","author":"PD Miller","year":"2016","unstructured":"Miller\u00a0PD, Pannacciulli\u00a0N, Brown\u00a0JP, Czerwinski\u00a0E, Nedergaard\u00a0BS, Bolognese\u00a0MA et\u00a0al (2016) Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. J\u00a0Clin Endocrinol Metab 101(8):3163\u20133170","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1620_CR14","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1002\/jbmr.4244","volume":"36","author":"D Farlay","year":"2021","unstructured":"Farlay\u00a0D, Rizzo\u00a0S, Ste-Marie\u00a0LG, Michou\u00a0L, Morin\u00a0SN, Qiu\u00a0S et\u00a0al (2021) Duration-dependent increase of human bone matrix mineralization in long-term bisphosphonate users with atypical femur fracture. J\u00a0Bone Miner Res 36(6):1031\u20131041","journal-title":"J Bone Miner Res"},{"issue":"5","key":"1620_CR15","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1007\/s11914-019-00524-y","volume":"17","author":"M Blank","year":"2019","unstructured":"Blank\u00a0M, Sims\u00a0NA (2019) Cellular processes by which osteoblasts and osteocytes control bone mineral deposition and maturation revealed by stage-specific EphrinB2 knockdown. Curr Osteoporos Rep 17(5):270\u2013280","journal-title":"Curr Osteoporos Rep"},{"issue":"7","key":"1620_CR16","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone\u00a0HG, Wagman\u00a0RB, Brandi\u00a0ML, Brown\u00a0JP, Chapurlat\u00a0R, Cummings\u00a0SR et\u00a0al (2017) 10\u00a0years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase\u00a03 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5(7):513\u2013523","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1620_CR17","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.bone.2016.01.002","volume":"85","author":"JC Lo","year":"2016","unstructured":"Lo\u00a0JC, Hui\u00a0RL, Grimsrud\u00a0CD, Chandra\u00a0M, Neugebauer\u00a0RS, Gonzalez\u00a0JR et\u00a0al (2016) The association of race\/ethnicity and risk of atypical femur fracture among older women receiving oral bisphosphonate therapy. Bone 85:142\u2013147","journal-title":"Bone"},{"issue":"7","key":"1620_CR18","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1177\/0192623317737066","volume":"45","author":"JP Brown","year":"2017","unstructured":"Brown\u00a0JP (2017) Antiresorptives: safety concerns-clinical perspective. Toxicol Pathol 45(7):859\u2013863","journal-title":"Toxicol Pathol"},{"key":"1620_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","volume":"105","author":"E Tsourdi","year":"2017","unstructured":"Tsourdi\u00a0E, Langdahl\u00a0B, Cohen-Solal\u00a0M, Aubry-Rozier\u00a0B, Eriksen\u00a0EF, Guanabens\u00a0N et\u00a0al (2017) Discontinuation of denosumab therapy for osteoporosis: a\u00a0systematic review and position statement by ECTS. Bone 105:11\u201317","journal-title":"Bone"},{"issue":"5","key":"1620_CR20","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1210\/clinem\/dgz295","volume":"105","author":"DM van de Laarschot","year":"2020","unstructured":"van de Laarschot\u00a0DM, McKenna\u00a0MJ, Abrahamsen\u00a0B, Langdahl\u00a0B, Cohen-Solal\u00a0M, Guanabens\u00a0N et\u00a0al (2020) Medical management of patients after atypical femur fractures: a\u00a0systematic review and recommendations from the European calcified tissue society. J\u00a0Clin Endocrinol Metab 105(5):1682\u20131699","journal-title":"J Clin Endocrinol Metab"},{"issue":"9999","key":"1620_CR21","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","volume":"386","author":"BZ Leder","year":"2015","unstructured":"Leder\u00a0BZ, Tsai\u00a0JN, Uihlein\u00a0AV, Wallace\u00a0PM, Lee\u00a0H, Neer\u00a0RM et\u00a0al (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a\u00a0randomised controlled trial. Lancet 386(9999):1147\u20131155","journal-title":"Lancet"},{"issue":"3","key":"1620_CR22","doi-asserted-by":"publisher","first-page":"105117","DOI":"10.1016\/j.jbspin.2020.105117","volume":"88","author":"G Carvajal Alegria","year":"2021","unstructured":"Carvajal Alegria\u00a0G, Garrigues\u00a0F, Bettacchioli\u00a0E, Loeuille\u00a0D, Saraux\u00a0A, Cornec\u00a0D et\u00a0al (2021) Tocilizumab controls bone turnover in early polymyalgia rheumatica. Joint Bone Spine 88(3):105117","journal-title":"Joint Bone Spine"},{"issue":"1","key":"1620_CR23","doi-asserted-by":"publisher","first-page":"17183","DOI":"10.1038\/s41598-023-44374-2","volume":"13","author":"G Adami","year":"2023","unstructured":"Adami\u00a0G, Orsolini\u00a0G, Rossini\u00a0M, Pedrollo\u00a0E, Fratucello\u00a0A, Fassio\u00a0A et\u00a0al (2023) Changes in bone turnover markers and bone modulators during abatacept treatment. Sci Rep 13(1):17183","journal-title":"Sci Rep"},{"issue":"2","key":"1620_CR24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jbspin.2014.10.015","volume":"82","author":"K Briot","year":"2015","unstructured":"Briot\u00a0K, Rouanet\u00a0S, Schaeverbeke\u00a0T, Etchepare\u00a0F, Gaudin\u00a0P, Perdriger\u00a0A et\u00a0al (2015) The effect of tocilizumab on bone mineral density, serum levels of Dickkopf\u20111 and bone remodeling markers in patients with rheumatoid arthritis. Joint Bone Spine 82(2):109\u2013115","journal-title":"Joint Bone Spine"},{"issue":"1","key":"1620_CR25","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10067-019-04771-3","volume":"39","author":"K Guly\u00e1s","year":"2020","unstructured":"Guly\u00e1s\u00a0K, Horv\u00e1th \u00c1, V\u00e9gh\u00a0E, Pusztai\u00a0A, Szentp\u00e9tery \u00c1, Peth\u00f6\u00a0Z et\u00a0al (2020) Effects of 1\u2011year anti-TNF\u2011\u03b1 therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis. Clin Rheumatol 39(1):167\u2013175","journal-title":"Clin Rheumatol"},{"issue":"12","key":"1620_CR26","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1093\/rheumatology\/kei082","volume":"44","author":"U Lange","year":"2005","unstructured":"Lange\u00a0U, Teichmann\u00a0J, M\u00fcller-Ladner\u00a0U, Strunk\u00a0J (2005) Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a\u00a0prospective open-label pilot study. Rheumatology 44(12):1546\u20131548","journal-title":"Rheumatology"},{"issue":"11","key":"1620_CR27","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1002\/art.42617","volume":"75","author":"D Simon","year":"2023","unstructured":"Simon\u00a0D, Minopoulou\u00a0I, Kemenes\u00a0S, Bayat\u00a0S, Tascilar\u00a0K, Mutlu\u00a0MY et\u00a0al (2023) Baricitinib improves bone properties and biomechanics in patients with rheumatoid arthritis: results of the prospective interventional BARE BONE trial. Arthritis Rheumatol 75(11):1923\u20131934","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"1620_CR28","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3390\/ijms21030865","volume":"21","author":"T Gaber","year":"2020","unstructured":"Gaber\u00a0T, Brinkman\u00a0ACK, Pienczikowski\u00a0J, Diesing\u00a0K, Damerau\u00a0A, Pfeiffenberger\u00a0M et\u00a0al (2020) Impact of Janus Kinase inhibition with tofacitinib on fundamental processes of bone healing. Int J Mol Sci 21(3):865","journal-title":"Int J Mol Sci"},{"issue":"8","key":"1620_CR29","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1007\/s00198-021-05871-0","volume":"32","author":"A Hamar","year":"2021","unstructured":"Hamar\u00a0A, Szekanecz\u00a0Z, Pusztai\u00a0A, Cz\u00f3kolyov\u00e1\u00a0M, V\u00e9gh\u00a0E, Peth\u0151\u00a0Z et\u00a0al (2021) Effects of one-year tofacitinib therapy on bone metabolism in rheumatoid arthritis. Osteoporos Int 32(8):1621\u20131629","journal-title":"Osteoporos Int"},{"issue":"1","key":"1620_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen\u00a0JS, Landew\u00e9\u00a0RBM, Bergstra\u00a0SA, Kerschbaumer\u00a0A, Sepriano\u00a0A, Aletaha\u00a0D et\u00a0al (2023) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 82(1):3\u201318","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1620_CR31","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel\u00a0L, Bathon\u00a0JM, England\u00a0BR, St. Clair\u00a0EW, Arayssi\u00a0T, Carandang\u00a0K et\u00a0al (2021) 2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res 73(7):924\u2013939","journal-title":"Arthritis Care Res"},{"issue":"7","key":"1620_CR32","doi-asserted-by":"publisher","first-page":"977","DOI":"10.3899\/jrheum.200310","volume":"48","author":"JG Hanly","year":"2021","unstructured":"Hanly\u00a0JG, Lethbridge\u00a0L (2021) Use of disease-modifying antirheumatic drugs, biologics, and corticosteroids in older patients with rheumatoid arthritis over 20 years. J\u00a0Rheumatol 48(7):977\u2013984","journal-title":"J Rheumatol"},{"issue":"7","key":"1620_CR33","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41584-024-01120-w","volume":"20","author":"F Buttgereit","year":"2024","unstructured":"Buttgereit\u00a0F, Palmowski\u00a0A, Bond\u00a0M, Adami\u00a0G, Dejaco\u00a0C (2024) Osteoporosis and fracture risk are multifactorial in patients with inflammatory rheumatic diseases. Nat Rev Rheumatol 20(7):417\u2013431","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"1620_CR34","doi-asserted-by":"publisher","first-page":"e000014","DOI":"10.1136\/rmdopen-2014-000014","volume":"1","author":"K Briot","year":"2015","unstructured":"Briot\u00a0K, Roux\u00a0C (2015) Glucocorticoid-induced osteoporosis. RMD Open 1(1):e14","journal-title":"RMD Open"},{"issue":"8","key":"1620_CR35","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41574-020-0341-0","volume":"16","author":"P Chotiyarnwong","year":"2020","unstructured":"Chotiyarnwong\u00a0P, McCloskey\u00a0EV (2020) Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. Nat Rev Endocrinol 16(8):437\u2013447","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"1620_CR36","doi-asserted-by":"publisher","first-page":"G92","DOI":"10.1152\/ajpgi.00317.2006","volume":"292","author":"S Huybers","year":"2007","unstructured":"Huybers\u00a0S, Naber\u00a0TH, Bindels\u00a0RJ, Hoenderop\u00a0JG (2007) Prednisolone-induced Ca2+ malabsorption is caused by diminished expression of the epithelial Ca2+ channel TRPV6. Am J Physiol Gastrointest Liver Physiol 292(1):G92\u20137","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"3","key":"1620_CR37","first-page":"664","volume":"158","author":"AY Sato","year":"2017","unstructured":"Sato\u00a0AY, Richardson\u00a0D, Cregor\u00a0M, Davis\u00a0HM, Au\u00a0ED, McAndrews\u00a0K et\u00a0al (2017) Glucocorticoids induce bone and muscle atrophy by tissue-specific mechanisms upstream of E3 ubiquitin ligases. Endocrinology 158(3):664\u2013677","journal-title":"Endocrinology"},{"issue":"6","key":"1620_CR38","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1359\/jbmr.2000.15.6.1001","volume":"15","author":"SC Manolagas","year":"2000","unstructured":"Manolagas\u00a0SC (2000) Corticosteroids and fractures: a\u00a0close encounter of the third cell kind. J\u00a0Bone Miner Res 15(6):1001\u20131005","journal-title":"J Bone Miner Res"},{"issue":"6","key":"1620_CR39","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1359\/jbmr.2000.15.6.993","volume":"15","author":"TP Van Staa","year":"2000","unstructured":"Van Staa\u00a0TP, Leufkens\u00a0HG, Abenhaim\u00a0L, Zhang\u00a0B, Cooper\u00a0C (2000) Use of oral corticosteroids and risk of fractures. J\u00a0Bone Miner Res 15(6):993\u20131000","journal-title":"J Bone Miner Res"},{"issue":"4","key":"1620_CR40","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1093\/rheumatology\/keab548","volume":"61","author":"S Abtahi","year":"2022","unstructured":"Abtahi\u00a0S, Driessen\u00a0JHM, Burden\u00a0AM, Souverein\u00a0PC, van den Bergh\u00a0JP, van Staa\u00a0TP et\u00a0al (2022) Low-dose oral glucocorticoid therapy and risk of osteoporotic fractures in patients with rheumatoid arthritis: a\u00a0cohort study using the clinical practice research datalink. Rheumatology 61(4):1448\u20131458","journal-title":"Rheumatology"},{"issue":"4","key":"1620_CR41","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1136\/annrheumdis-2020-218758","volume":"80","author":"S Abtahi","year":"2021","unstructured":"Abtahi\u00a0S, Driessen\u00a0JHM, Burden\u00a0AM, Souverein\u00a0PC, van den Bergh\u00a0JP, van Staa\u00a0TP et\u00a0al (2021) Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a\u00a0population-based cohort study. Ann Rheum Dis 80(4):423\u2013431","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1620_CR42","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1136\/annrheumdis-2022-222339","volume":"81","author":"E Wiebe","year":"2022","unstructured":"Wiebe\u00a0E, Huscher\u00a0D, Schaumburg\u00a0D, Palmowski\u00a0A, Hermann\u00a0S, Buttgereit\u00a0T et\u00a0al (2022) Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease. Ann Rheum Dis 81(9):1313\u20131322","journal-title":"Ann Rheum Dis"},{"issue":"02","key":"1620_CR43","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1055\/a-2034-6086","volume":"32","author":"R Schmidmaier","year":"2023","unstructured":"Schmidmaier\u00a0R, Hadji\u00a0P, Kern\u00a0P, Drey\u00a0M, Jakob\u00a0F, Thomasius\u00a0F (2023of) Recommendations for the pharmacological treatment of osteoporosis\u2014update 2023 of the German osteoporosis guideline. Osteologie 32(02):115\u2013122","journal-title":"Osteologie"},{"issue":"11","key":"1620_CR44","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1002\/art.24879","volume":"60","author":"KG Saag","year":"2009","unstructured":"Saag\u00a0KG, Zanchetta\u00a0JR, Devogelaer\u00a0JP, Adler\u00a0RA, Eastell\u00a0R, See\u00a0K et\u00a0al (2009) Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a\u00a0randomized, double-blind, controlled trial. Arthritis Rheum 60(11):3346\u20133355","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1620_CR45","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3899\/jrheum.090411","volume":"37","author":"JP Devogelaer","year":"2010","unstructured":"Devogelaer\u00a0JP, Adler\u00a0RA, Recknor\u00a0C, See\u00a0K, Warner\u00a0MR, Wong\u00a0M et\u00a0al (2010) Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis. J\u00a0Rheumatol 37(1):141\u2013148","journal-title":"J Rheumatol"},{"issue":"10","key":"1620_CR46","first-page":"Cd001347","volume":"10","author":"CS Allen","year":"2016","unstructured":"Allen\u00a0CS, Yeung\u00a0JH, Vandermeer\u00a0B, Homik\u00a0J (2016) Bisphosphonates for steroid-induced osteoporosis. Cochrane Database Syst Rev 10(10):Cd1347","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"1620_CR47","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S2213-8587(18)30075-5","volume":"6","author":"KG Saag","year":"2018","unstructured":"Saag\u00a0KG, Wagman\u00a0RB, Geusens\u00a0P, Adachi\u00a0JD, Messina\u00a0OD, Emkey\u00a0R et\u00a0al (2018) Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a\u00a0multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol 6(6):445\u2013454","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"1620_CR48","first-page":"1305","volume":"31","author":"O Di Munno","year":"2004","unstructured":"Di Munno\u00a0O, Mazzantini\u00a0M, Sinigaglia\u00a0L, Bianchi\u00a0G, Minisola\u00a0G, Muratore\u00a0M et\u00a0al (2004) Effect of low dose methotrexate on bone density in women with rheumatoid arthritis: results from a\u00a0multicenter cross-sectional study. J\u00a0Rheumatol 31(7):1305\u20131309","journal-title":"J Rheumatol"},{"issue":"3","key":"1620_CR49","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1002\/1097-0142(197003)25:3<580::AID-CNCR2820250313>3.0.CO;2-M","volume":"25","author":"AH Ragab","year":"1970","unstructured":"Ragab\u00a0AH, Frech\u00a0RS, Vietti\u00a0TJ (1970) Osteoporotic fractures secondary to methotrexate therapy of acute leukemia in remission. Cancer 25(3):580\u2013585","journal-title":"Cancer"},{"issue":"6394","key":"1620_CR50","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1136\/bmj.287.6394.762-a","volume":"287","author":"G Ansell","year":"1983","unstructured":"Ansell\u00a0G, Evans\u00a0S, Jackson\u00a0CT, Lewis-Jones\u00a0S (1983) Cytotoxic drugs for non-neoplastic disease. Br Med\u00a0J 287(6394):762","journal-title":"Br Med J"},{"issue":"2","key":"1620_CR51","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00198-020-05664-x","volume":"32","author":"F Robin","year":"2021","unstructured":"Robin\u00a0F, Cadiou\u00a0S, Albert\u00a0JD, Bart\u00a0G, Coiffier\u00a0G, Guggenbuhl\u00a0P (2021) Methotrexate osteopathy: five cases and systematic literature review. Osteoporos Int 32(2):225\u2013232","journal-title":"Osteoporos Int"},{"key":"1620_CR52","doi-asserted-by":"publisher","first-page":"151952","DOI":"10.1016\/j.semarthrit.2022.151952","volume":"52","author":"N Ruffer","year":"2022","unstructured":"Ruffer\u00a0N, Krusche\u00a0M, Beil\u00a0FT, Amling\u00a0M, K\u00f6tter\u00a0I, Rolvien\u00a0T (2022) Clinical features of methotrexate osteopathy in rheumatic musculoskeletal disease: a\u00a0systematic review. Semin Arthritis Rheum 52:151952","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"1620_CR53","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00223-020-00765-5","volume":"108","author":"T Rolvien","year":"2021","unstructured":"Rolvien\u00a0T, Jandl\u00a0NM, St\u00fcrznickel\u00a0J, Beil\u00a0FT, K\u00f6tter\u00a0I, Oheim\u00a0R et\u00a0al (2021) Clinical and radiological characterization of patients with immobilizing and progressive stress fractures in methotrexate osteopathy. Calcif Tissue Int 108(2):219\u2013230","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"1620_CR54","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/8756-3282(94)00032-U","volume":"16","author":"DL Wheeler","year":"1995","unstructured":"Wheeler\u00a0DL, Vander Griend\u00a0RA, Wronski\u00a0TJ, Miller\u00a0GJ, Keith\u00a0EE, Graves\u00a0JE (1995) The short- and long-term effects of methotrexate on the rat skeleton. Bone 16(2):215\u2013221","journal-title":"Bone"},{"issue":"5","key":"1620_CR55","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.bone.2007.07.021","volume":"41","author":"CJ Xian","year":"2007","unstructured":"Xian\u00a0CJ, Cool\u00a0JC, Scherer\u00a0MA, Macsai\u00a0CE, Fan\u00a0C, Covino\u00a0M et\u00a0al (2007) Cellular mechanisms for methotrexate chemotherapy-induced bone growth defects. Bone 41(5):842\u2013850","journal-title":"Bone"},{"issue":"2","key":"1620_CR56","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/art.1780370208","volume":"37","author":"KP May","year":"1994","unstructured":"May\u00a0KP, West\u00a0SG, Mcdermott\u00a0MT, Huffer\u00a0WE (1994) The effect of low-dose methotrexate on bone metabolism and histomorphometry in rats. Arthritis Rheum 37(2):201\u2013206","journal-title":"Arthritis Rheum"},{"key":"1620_CR57","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/903097","author":"C Fan","year":"2011","unstructured":"Fan\u00a0C, Georgiou\u00a0K, King\u00a0TJ, Chen\u00a0X (2011) Methotrexate toxicity in growing long bones of young rats: a\u00a0model for studying cancer chemotherapy-induced bone growth defects in children. Biomed Res Int. https:\/\/doi.org\/10.1155\/2011\/903097","journal-title":"Biomed Res Int"},{"issue":"1","key":"1620_CR58","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ajpath.2012.03.037","volume":"181","author":"TJ King","year":"2012","unstructured":"King\u00a0TJ, Georgiou\u00a0KR, Cool\u00a0JC, Scherer\u00a0MA, Ang\u00a0ESM, Foster\u00a0BK et\u00a0al (2012) Methotrexate chemotherapy promotes osteoclast formation in the long bone of rats via increased pro-inflammatory cytokines and enhanced NF-&#x3ba;B activation. Am J Pathol 181(1):121\u2013129","journal-title":"Am J Pathol"},{"issue":"7","key":"1620_CR59","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1002\/jcp.23034","volume":"227","author":"T Shandala","year":"2012","unstructured":"Shandala\u00a0T, Shen Ng\u00a0Y, Hopwood\u00a0B, Yip\u00a0Y\u2011C, Foster\u00a0BK, Xian\u00a0CJ (2012) The role of osteocyte apoptosis in cancer chemotherapy-induced bone loss. J\u00a0Cell Physiol 227(7):2889\u20132897","journal-title":"J Cell Physiol"},{"issue":"4","key":"1620_CR60","first-page":"e37478","volume":"15","author":"CS Puvvada","year":"2023","unstructured":"Puvvada\u00a0CS, Soomro\u00a0FH, Osman\u00a0HA, Haridi\u00a0M, Gonzalez\u00a0NA, Dayo\u00a0SM et\u00a0al (2023) Efficacy and safety of teriparatide in improving fracture healing and callus formation: a\u00a0systematic review. Cureus 15(4):e37478","journal-title":"Cureus"},{"issue":"5","key":"1620_CR61","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00223-024-01290-5","volume":"115","author":"FN von Brackel","year":"2024","unstructured":"von Brackel\u00a0FN, Grambeck\u00a0J, Barvencik\u00a0F, Amling\u00a0M, Oheim\u00a0R (2024) MTX osteopathy versus osteoporosis including response to treatment data\u2014a retrospective single center study including 172 patients. Calcif Tissue Int 115(5):599\u2013610","journal-title":"Calcif Tissue Int"},{"issue":"8","key":"1620_CR62","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.3899\/jrheum.220758","volume":"50","author":"B Buehring","year":"2023","unstructured":"Buehring\u00a0B, Al-Azem\u00a0N, Kiltz\u00a0U, Fruth\u00a0M, Andreica\u00a0I, Kiefer\u00a0D et\u00a0al (2023) High prevalence of foot insufficiency fractures in patients with inflammatory rheumatic musculoskeletal diseases. J\u00a0Rheumatol 50(8):1071\u20131077","journal-title":"J Rheumatol"},{"issue":"10","key":"1620_CR63","doi-asserted-by":"publisher","first-page":"e10393","DOI":"10.1002\/jbm4.10393","volume":"4","author":"L Carbone","year":"2020","unstructured":"Carbone\u00a0L, Vasan\u00a0S, Elam\u00a0R, Gupta\u00a0S, Tolaymat\u00a0O, Crandall\u00a0C et\u00a0al (2020) The association of methotrexate, sulfasalazine, and hydroxychloroquine use with fracture in postmenopausal women with rheumatoid arthritis: findings from the women\u2019s health initiative. JBMR Plus 4(10):e10393","journal-title":"JBMR Plus"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01620-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-025-01620-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01620-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T11:49:37Z","timestamp":1740570577000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-025-01620-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1620"],"URL":"https:\/\/doi.org\/10.1007\/s00393-025-01620-4","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"4 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"E.\u00a0Wiebe, P.\u00a0Hoff und F.\u00a0Buttgereit geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Alle beschriebenen Untersuchungen am Menschen oder an menschlichem Gewebe wurden mit Zustimmung der zust\u00e4ndigen Ethikkommission, im Einklang mit nationalem Recht sowie gem\u00e4\u00df der Deklaration von Helsinki von 1975 (in der aktuellen, \u00fcberarbeiteten Fassung) durchgef\u00fchrt. Von allen beteiligten Patient\/-innen liegt eine Einverst\u00e4ndniserkl\u00e4rung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}